Following Major Acquisitions and Subsequent Growth in Client Campaign Bookings in November, Company Reiterates Outlook for Record Full Year 2024 Pro Forma Revenue with Positive Adjusted EBITDA NEW ...

No­vo Nordisk’s once-a-day sick­le cell dis­ease drug etavopi­vat cut the rate of pain crises in a year­long mid-stage study.